Patents by Inventor Scott W. Altmann

Scott W. Altmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR MEASURING HDL SUBPOPULATIONS
    Publication number: 20140243233
    Abstract: This invention provides a capture/detection antibody-based method for measuring the amount of a high density lipoprotein (HDL) subpopulation present in a sample, wherein each particle of the HDL subpopulation being measured is characterized by the presence of a plurality of defined protein epitopes. This invention also provides related analytical and diagnostic methods, as well as kits for performing same.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 28, 2014
    Applicant: HDL Apomics LLC
    Inventor: Scott W. Altmann
  • NRIP1 regulation of apolipoprotein A1
    Patent number: 8257921
    Abstract: The present invention provides, in part, methods for identifying inhibitors of NRIP1 and methods of using such inhibitors. Methods of treating NRIP1-mediated disorders using NRIP1 inhibitor are also provided.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 4, 2012
    Assignee: Schering Corporation
    Inventors: Xiaorui Yao, Scott W. Altmann, Liji Zhu
  • NPC1L1 orthologues
    Patent number: 8212016
    Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: July 3, 2012
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
  • NPC1L1 (NPC3) AND METHODS OF USE THEREOF
    Publication number: 20120079616
    Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 29, 2012
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • Use of azetidinone compounds
    Patent number: 7723020
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: May 25, 2010
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • NPC1L1 orthologues
    Publication number: 20090098128
    Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.
    Type: Application
    Filed: February 22, 2007
    Publication date: April 16, 2009
    Inventors: Scott W. Altmann, Xiaorui Yao, Kim Ann O'Neill, Brian E. Hawes
  • Use of azetidinone compounds
    Patent number: 7144696
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: December 5, 2006
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • NPC1L1 (NPC3) and methods of use thereof
    Patent number: 7135556
    Abstract: We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: November 14, 2006
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • Use of azetidinone compounds
    Patent number: 6933107
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: August 23, 2005
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • NPC1L1 (NPC3) and methods of use thereof
    Publication number: 20040161838
    Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: December 16, 2003
    Publication date: August 19, 2004
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • NPC1L1 (NPC3) and methods of use thereof
    Publication number: 20040137467
    Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: August 22, 2003
    Publication date: July 15, 2004
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • NPC1L1 (NPC3) and methods of use thereof
    Publication number: 20040132058
    Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: September 16, 2003
    Publication date: July 8, 2004
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • NPC1L1 (NPC3) and methods of use thereof
    Publication number: 20040093629
    Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: July 17, 2003
    Publication date: May 13, 2004
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Lu Quan Wang, Michael P. Graziano
  • Use of azetidinone compounds
    Publication number: 20030215869
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Application
    Filed: May 15, 2003
    Publication date: November 20, 2003
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Use of azetidinone compounds
    Patent number: 6632933
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 14, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Use of azetidinone compounds
    Patent number: 6593078
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 15, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Use of azetidinone compounds
    Publication number: 20020009714
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Application
    Filed: July 30, 2001
    Publication date: January 24, 2002
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Mutational variants of mammalian proteins
    Patent number: 6225446
    Abstract: Muteins, which are mutational variants of mammalian proteins. Particular positions of natural proteins are identified as critical in providing various different activities. Specific embodiments demonstrate properties of variations at these positions.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: May 1, 2001
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein